Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC.
Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC. Bioorg Med Chem Lett. 2019 07 01; 29(13):1565-1571.